Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Titel:
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Auteur:
Yau, Thomas Park, Joong-Won Finn, Richard S Cheng, Ann-Lii Mathurin, Philippe Edeline, Julien Kudo, Masatoshi Harding, James J Merle, Philippe Rosmorduc, Olivier Wyrwicz, Lucjan Schott, Eckart Choo, Su Pin Kelley, Robin Kate Sieghart, Wolfgang Assenat, Eric Zaucha, Renata Furuse, Junji Abou-Alfa, Ghassan K El-Khoueiry, Anthony B Melero, Ignacio Begic, Damir Chen, Gong Neely, Jaclyn Wisniewski, Tami Tschaika, Marina Sangro, Bruno